Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

Pharmacokinetic/pharmacodynamic profile of posaconazole.

Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H.

Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000. Review.

PMID:
20481649
2.

Posaconazole: clinical pharmacology and potential for management of fungal infections.

Groll AH, Walsh TJ.

Expert Rev Anti Infect Ther. 2005 Aug;3(4):467-87. Review.

PMID:
16107193
3.

Pharmacokinetic/pharmacodynamic profile of voriconazole.

Theuretzbacher U, Ihle F, Derendorf H.

Clin Pharmacokinet. 2006;45(7):649-63. Review.

PMID:
16802848
4.

In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM.

Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15.

5.

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent.

Nagappan V, Deresinski S.

Clin Infect Dis. 2007 Dec 15;45(12):1610-7. doi: 10.1086/523576. Review.

PMID:
18190324
7.

Posaconazole: a broad-spectrum triazole antifungal.

Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II.

Lancet Infect Dis. 2005 Dec;5(12):775-85. Review.

PMID:
16310149
8.

Posaconazole: an extended-spectrum triazole antifungal agent.

Schiller DS, Fung HB.

Clin Ther. 2007 Sep;29(9):1862-86. Review.

PMID:
18035188
9.

Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.

Morris MI.

Am J Health Syst Pharm. 2009 Feb 1;66(3):225-36. doi: 10.2146/ajhp070532. Review. Erratum in: Am J Health Syst Pharm. 2010 May 1;67(9):698.

PMID:
19179636
10.

Posaconazole: Use in the Prophylaxis and Treatment of Fungal Infections.

Clark NM, Grim SA, Lynch JP 3rd.

Semin Respir Crit Care Med. 2015 Oct;36(5):767-85. doi: 10.1055/s-0035-1562902. Epub 2015 Sep 23. Review.

PMID:
26398542
11.
12.

New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.

Fera MT, La Camera E, De Sarro A.

Expert Rev Anti Infect Ther. 2009 Oct;7(8):981-98. doi: 10.1586/eri.09.67. Review.

PMID:
19803707
13.

Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview.

Lipp HP.

Br J Clin Pharmacol. 2010 Oct;70(4):471-80. doi: 10.1111/j.1365-2125.2010.03680.x.

14.

Posaconazole: a new antifungal weapon.

Aperis G, Alivanis P.

Rev Recent Clin Trials. 2011 Sep;6(3):204-19. Review.

PMID:
21682687
15.

Echinocandin antifungal drugs in fungal infections: a comparison.

Chen SC, Slavin MA, Sorrell TC.

Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Review. Erratum in: Drugs. 2011 Jan 22;71(2):253.

PMID:
21175238
17.

Posaconazole: a next-generation triazole antifungal.

Farowski F, Vehreschild JJ, Cornely OA.

Future Microbiol. 2007 Jun;2(3):231-43.

PMID:
17661696
18.

In vitro antifungal activity of posaconazole against various pathogenic fungi.

Uchida K, Yokota N, Yamaguchi H.

Int J Antimicrob Agents. 2001 Aug;18(2):167-72.

PMID:
11516940
19.

In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.

Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I, Kobayashi K, Shimma N, Page MG, Arisawa M.

Int J Antimicrob Agents. 2010 Oct;36(4):324-31. doi: 10.1016/j.ijantimicag.2010.06.003. Epub 2010 Jul 31.

PMID:
20674282

Supplemental Content

Support Center